Summary statistics from meta-analyses of prevalence studies on hepatitis B virus infection among populations in Cameroon using random effects model and arcsine transformations
| Group | #Studies | #Participants | #Cases | Prevalence, % (95% CI) | I², % | p-heterogeneity | p-Egger's test | p-difference |
| Populations | ||||||||
| Overall | 27 | 100 501 | 13 185 | 9.5 (7.9 to 11.4) | 98.6 | <0.001 | 0.017 | 0.567 |
| General | 5 | 7397 | 760 | 7.1 (2.6 to 13.5) | 98.5 | <0.001 | ||
| Blood donors | 12 | 68 474 | 9196 | 10.5 (8.7 to 12.4) | 97.5 | <0.001 | ||
| Pregnant women | 10 | 24 630 | 3229 | 9.8 (5.4 to 15.4) | 99.2 | <0.001 | ||
| Regions | ||||||||
| Overall | 30 | 96 134 | 12 617 | 9.2 (7.1 to 11.5) | 97.9 | <0.001 | 0.004 | <0.001 |
| Centre | 10 | 60 372 | 8258 | 9.1 (7.1 to 11.3) | 97.5 | <0.001 | ||
| East | 1 | 364 | 37 | 10.2 (7.5 to 13.7) | - | - | ||
| Far-North | 3 | 15 859 | 2834 | 15.8 (13.1 to 18.6) | 82.2 | <0.001 | ||
| Littoral | 6 | 9085 | 628 | 6.7 (4.0 to 10.1) | 96.3 | <0.001 | ||
| North | 1 | 1276 | 259 | 20.3 (18.2 to 22.6) | - | - | ||
| North-West | 2 | 561 | 39 | 6.9 (5.0 to 9.2) | 99.3 | <0.001 | ||
| South | 1 | 101 | 19 | 18.8 (12.4 to 27.5) | - | - | ||
| South-West | 5 | 7534 | 502 | 8.0 (5.5 to 10.8) | 92.8 | <0.001 | ||
| West | 1 | 982 | 41 | 4.2 (3.1 to 5.6) | - | - | ||
| Settings | ||||||||
| Overall | 22 | 86 439 | 12 353 | 10.0 (8.6 to 11.6) | 97.4 | <0.001 | 0.006 | 0.005 |
| Rural | 7 | 17 799 | 3159 | 13.3 (10.6 to 16.2) | 91.8 | <0.001 | ||
| Urban | 15 | 68 640 | 9194 | 9.0 (7.3 to 10.7) | 97.4 | <0.001 | ||
| Sex | ||||||||
| Overall | 21 | 44 951 | 5669 | 9.3 (7.1 to 11.8) | 98.8 | <0.001 | 0.113 | 0.168 |
| Female | 15 | 26 614 | 224 | 8.5 (5.2 to 12.6) | 85.9 | <0.001 | ||
| Male | 6 | 18 337 | 389 | 11.6 (10.1 to 13.1) | 98.4 | <0.001 | ||
| Sites | ||||||||
| Overall | 27 | 1 00 501 | 13 185 | 9.5 (7.9 to 11.3) | 98.6 | <0.001 | 0.017 | 0.954 |
| Hospital-based | 23 | 93 867 | 12 430 | 9.5 (7.7 to 11.5) | 98.8 | <0.001 | ||
| Population-based | 4 | 6634 | 755 | 9.7 (5.6 to 14.7) | 96.5 | <0.001 | ||
| Timing of data collection | ||||||||
| Overall | 27 | 1 00 501 | 13 185 | 9.5 (7.9 to 11.4) | 98.6 | <0.001 | 0.014 | 0.110 |
| Retrospective | 5 | 17 189 | 2079 | 11.4 (10.3 to 12.5) | 73.1 | 0.010 | ||
| Prospective | 22 | 83 312 | 11 106 | 9.3 (7.2 to 11.6) | 98.9 | <0.001 | ||
| Risk of bias | ||||||||
| Overall | 27 | 1 00 501 | 13 185 | 9.5 (7.9 to 11.4) | 98.6 | <0.001 | 0.017 | 0.435 |
| High | 4 | 17 279 | 2847 | 8.2 (2.3 to 17.2) | 99.4 | <0.001 | ||
| Moderate | 11 | 58 822 | 7380 | 9.0 (5.9 to 12.7) | 99.1 | <0.001 | ||
| Low | 12 | 24 637 | 2958 | 11.0 (10.2 to 11.9) | 69.6 | <0.001 | ||
| Status regarding implementation of the HBV universal immunisation | ||||||||
| Overall | 18 | 28 761 | 3156 | 8.4 (6.8 to 10.1) | 95.5 | <0.001 | 0.003 | <0.001 |
| Before | 17 | 27 998 | 3151 | 9.2 (7.9 to 10.5) | 91.4 | <0.001 | ||
| After | 1 | 765 | 5 | 0.7 (0.3 to 1.5) | - | - | ||
| HBV screening tools | ||||||||
| Overall | 21 | 47 396 | 5700 | 9.3 (7.0 to 12.0) | 98.7 | <0.001 | 0.193 | 0.239 |
| Enzyme immunoassay | 3 | 2023 | 98 | 4.2 (0.4 to 11.2) | 97.2 | <0.001 | ||
| Enzyme-linked immunoassay | 4 | 2580 | 261 | 10.0 (8.4 to 11.8) | 51.3 | 0.10 | ||
| Rapid diagnostic test | 14 | 42 793 | 5341 | 10.5 (7.5 to 13.8) | 99.0 | <0.001 |